Limits...
Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma.

Zeng YP, Yang ZR, Guo XF, Jun W, Dong WG - Oncol Lett (2014)

Bottom Line: Furthermore, the percentage of apoptotic cells was markedly increased in the combined treatment group when compared with that of the individual treatment groups, in vitro and in vivo.Treatment with 5-FU was found to decrease the tumor volume by 76.26% and tumor weight by 49.86%.These results suggest that puerarin and 5-FU exhibit a synergistic treatment effect on the HCC SMMC7721 cell line.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430062, P.R. China.

ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common types of human malignancy worldwide, which is becoming increasingly resistant to traditional drug treatments. Puerarin combined with 5-fluorouracil (5-FU) may be a useful treatment for liver cancer. The primary aim of the present study was to determine whether combined treatment with 5-FU and puerarin is more effective against the hepatocellular carcinoma (HCC) cell line, SMMC7721, than treatment with 5-FU or puerarin alone. The growth inhibition of SMMC7721 cells by puerarin or 5-FU alone or in combination was determined by the Cell Counting Kit-8 assay, in vitro. Apoptotic morphological features and the percentage of apoptotic cells were detected using Hoechst 33258 staining and an Annexin V/PI apoptosis kit, respectively. In addition, a tumor xenograft model was established in nude mice using SMMC7721 cells. Puerarin and 5-FU alone or in combination were injected into the mice, and the inhibition of tumor growth was evaluated by monitoring tumor volume and weight. Treatment with 6,400 or 640 μM 5-FU resulted in growth inhibition of 95.56±0.81 and 75.91±3.54%, respectively. The combination index values were <1 when the fraction of affected cells was between 0.2555 and 0.7420. Furthermore, the percentage of apoptotic cells was markedly increased in the combined treatment group when compared with that of the individual treatment groups, in vitro and in vivo. Individual treatment with puerarin resulted in a tumor volume inhibition rate (IR) of 70.58% and a tumor weight IR of 46.20%. Treatment with 5-FU was found to decrease the tumor volume by 76.26% and tumor weight by 49.86%. In the combined treatment group, the tumor volume and weight IRs were 93.11 and 75.21%, respectively. A marked increase in the inhibition of tumor growth and the number of apoptotic cells in response to combined treatment with puerarin and 5-FU was identified with no observed liver or renal toxicity. These results suggest that puerarin and 5-FU exhibit a synergistic treatment effect on the HCC SMMC7721 cell line.

No MeSH data available.


Related in: MedlinePlus

Effect of puerarin or 5-FU alone on SMMC7721 cell proliferation. (A) The proliferation of SMMC7721 cells was inhibited by puerarin in a dose-dependent manner (P<0.01). (B) Similar results were obtained for 5-FU (P<0.01). 5-FU, 5-fluorouracil.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214471&req=5

f1-ol-08-06-2436: Effect of puerarin or 5-FU alone on SMMC7721 cell proliferation. (A) The proliferation of SMMC7721 cells was inhibited by puerarin in a dose-dependent manner (P<0.01). (B) Similar results were obtained for 5-FU (P<0.01). 5-FU, 5-fluorouracil.

Mentions: The inhibition of SMMC7721 proliferation by puerarin and 5-FU was assessed following 48 h of drug exposure and 24 h of culture in drug-free medium. After 48 h of treatment, in vitro SMMC7721 cell growth was significantly inhibited in a dose-dependent manner (P<0.01; Fig. 1). The mean ± SD rate of inhibition by puerarin was 19.51±0.72% at a concentration of 400 μM, and 95.56±0.81% at a concentration of 6,400 μM. The rate of growth inhibition by 5-FU at 40 μM was 38.83±0.63%, while the rate was 75.91±3.54% at 640 μM.


Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma.

Zeng YP, Yang ZR, Guo XF, Jun W, Dong WG - Oncol Lett (2014)

Effect of puerarin or 5-FU alone on SMMC7721 cell proliferation. (A) The proliferation of SMMC7721 cells was inhibited by puerarin in a dose-dependent manner (P<0.01). (B) Similar results were obtained for 5-FU (P<0.01). 5-FU, 5-fluorouracil.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214471&req=5

f1-ol-08-06-2436: Effect of puerarin or 5-FU alone on SMMC7721 cell proliferation. (A) The proliferation of SMMC7721 cells was inhibited by puerarin in a dose-dependent manner (P<0.01). (B) Similar results were obtained for 5-FU (P<0.01). 5-FU, 5-fluorouracil.
Mentions: The inhibition of SMMC7721 proliferation by puerarin and 5-FU was assessed following 48 h of drug exposure and 24 h of culture in drug-free medium. After 48 h of treatment, in vitro SMMC7721 cell growth was significantly inhibited in a dose-dependent manner (P<0.01; Fig. 1). The mean ± SD rate of inhibition by puerarin was 19.51±0.72% at a concentration of 400 μM, and 95.56±0.81% at a concentration of 6,400 μM. The rate of growth inhibition by 5-FU at 40 μM was 38.83±0.63%, while the rate was 75.91±3.54% at 640 μM.

Bottom Line: Furthermore, the percentage of apoptotic cells was markedly increased in the combined treatment group when compared with that of the individual treatment groups, in vitro and in vivo.Treatment with 5-FU was found to decrease the tumor volume by 76.26% and tumor weight by 49.86%.These results suggest that puerarin and 5-FU exhibit a synergistic treatment effect on the HCC SMMC7721 cell line.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430062, P.R. China.

ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common types of human malignancy worldwide, which is becoming increasingly resistant to traditional drug treatments. Puerarin combined with 5-fluorouracil (5-FU) may be a useful treatment for liver cancer. The primary aim of the present study was to determine whether combined treatment with 5-FU and puerarin is more effective against the hepatocellular carcinoma (HCC) cell line, SMMC7721, than treatment with 5-FU or puerarin alone. The growth inhibition of SMMC7721 cells by puerarin or 5-FU alone or in combination was determined by the Cell Counting Kit-8 assay, in vitro. Apoptotic morphological features and the percentage of apoptotic cells were detected using Hoechst 33258 staining and an Annexin V/PI apoptosis kit, respectively. In addition, a tumor xenograft model was established in nude mice using SMMC7721 cells. Puerarin and 5-FU alone or in combination were injected into the mice, and the inhibition of tumor growth was evaluated by monitoring tumor volume and weight. Treatment with 6,400 or 640 μM 5-FU resulted in growth inhibition of 95.56±0.81 and 75.91±3.54%, respectively. The combination index values were <1 when the fraction of affected cells was between 0.2555 and 0.7420. Furthermore, the percentage of apoptotic cells was markedly increased in the combined treatment group when compared with that of the individual treatment groups, in vitro and in vivo. Individual treatment with puerarin resulted in a tumor volume inhibition rate (IR) of 70.58% and a tumor weight IR of 46.20%. Treatment with 5-FU was found to decrease the tumor volume by 76.26% and tumor weight by 49.86%. In the combined treatment group, the tumor volume and weight IRs were 93.11 and 75.21%, respectively. A marked increase in the inhibition of tumor growth and the number of apoptotic cells in response to combined treatment with puerarin and 5-FU was identified with no observed liver or renal toxicity. These results suggest that puerarin and 5-FU exhibit a synergistic treatment effect on the HCC SMMC7721 cell line.

No MeSH data available.


Related in: MedlinePlus